greenlightpa.com

What It Is

GreenlightPA is a lightweight web tool for medical clinics, designed to reduce the manual confusion involved in medication prior authorization (PA) checks. Based on state, insurer, and drug policy, it helps teams quickly determine whether a medication requires PA and whether it is likely to be covered. The current messaging indicates a focus on dermatology use cases in California, Massachusetts, New York, and Washington in the United States.

Core Features and Product Capabilities

The core feature is instant PA checking: users can combine factors such as insurer, diagnosis, and age to quickly assess the coverage likelihood for medications such as Dupixent and Stelara. The new Drug Recommender feature goes beyond checking a single medication. By entering a patient’s age, insurer, disease scope, and prior topical or biologic treatment history, it ranks the likelihood of approval for Dupixent and Adbry under Aetna, Cigna, and UnitedHealthcare, while also indicating which materials are still missing. It also takes into account age restrictions, step therapy, BSA thresholds, special-site pathways such as hands and feet, and authorization duration.

Pricing, Deployment, and Security

The main content does not disclose plans, pricing, payment methods, or commercial terms; it only provides entry points such as Open the App and Request a Demo. In terms of deployment, it is a web-based tool and emphasizes that it requires no login, no PHI, and runs locally in the browser, making it suitable for clinic front-desk or clinical support staff who want low-friction lookups. On security, No PHI and No Login help reduce the burden of handling sensitive data, but the page does not mention formal compliance certifications or controls such as HIPAA, SOC 2, or audit logs.

Pros and Cons

Its strengths are a low learning curve, fast responses, no need for an account system, and reliance on publicly available insurer policies. When policy citations are missing, it indicates that transparently. It can also be customized around a clinic’s commonly used drugs and insurers, and its design suggests room to expand into more states, specialties, and drug sets. The limitations are also clear: current coverage is limited, and some insurer-drug combinations may still need validation. There is no visible information about EHR/EMR integration, APIs, team permissions, pricing, or SLAs, leaving a gap versus the enterprise-level disclosures typically needed for procurement by larger healthcare organizations.

Who It’s For and Access from China

GreenlightPA is better suited to dermatology clinics in specific U.S. states for quick pre-submission PA assessment and materials preparation. It is not suitable as a tool for China’s local public medical insurance or commercial insurance rules. The main content provides no information on access from China, so this would need to be tested directly; payment methods are likewise undisclosed. For China-based medical scenarios, alternatives should prioritize local solutions within the ecosystems of medical insurance cost control, prescription review, or hospital information systems.